CRANBURY, NJ — Solco Healthcare is proud to announce its FDA approval for Doxycycline Hyclate delayed-release tablets, 150mg and 200mg, which are AB-rated equivalents to Doryx® by Mayne Pharmaceutical.
“This new product launch demonstrates the capabilities of the Prinston/Solco team in developing, manufacturing and bringing a difficult to formulate product to market. As one of fastest growing US generic companies, we are pleased to be the first wave company to make high-quality Doxycycline Delayed Release tablets in 200mg and 150mg strengths available for patients in the US,” said Hai Wang, President of Solco Healthcare. Doxycycline Hyclate DR tablet is an oral antibacterial drug that is used in combination with other medicines to treat severe acne. According to IMS Health, total market sales for both strengths for the last twelve months ending September 2016 were $147.7 million.
Solco Healthcare will market Doxycycline Hyclate delayed-release tablets in 100 count bottles for the 150mg strength and in 60 count bottles for the 200mg strength. Solco anticipates launching these products in the very near future. Please contact your Solco Healthcare National Accounts Director or customer service at 1-888-869-8008 for more information.